biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Hey narmac

<< Previous

Bullboard Posts

Next >>

Comment by zwerp2000on Jan 25, 2023 8:15am

100 Views

Post# 35244559

RE:RE:RE:Hey narmac

But again, there are debt obligations coming due very soon. The company can't pay them, The company can't raise any significant funds to pay them or continue operations. The company had years to address this and failed to do so. My belief is that xb3 is junk and worthless which is the real reason but either way, the company does not have the means to do anything. The company did absolutely nothing over the years so why do people think this will change over the next several weeks? No, what is likely to happen is that the company will wind down operations and cease to exist. The white knight some of you grossly mistaken was coming to save you ain't coming. Game over

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China